Global Forecasting Strategy for Rare Immunodeficiency Launch

A global pharmaceutical client with a strong Immunology portfolio planned to launch a new treatment for adults with an ultra-rare immunodeficiency disease. The client’s commercial excellence team required a robust, patient-based forecasting model to accurately estimate market potential, identify the treatable patient population, and project revenue. Key requirements included building an automated events calculation engine to assess the impact of both new and existing products, incorporating flexible scenarios to account for potential delays in product launch timelines, considering possible extensions of the Loss of Exclusivity (LOE), and automating the conversion of annual revenue estimates into monthly projections across multiple global geographies.